First CD79b Targeted Therapy! Roche Antibody Drug Conjugate Polatuzumab Vedotin is Given Priority Review by FDA in the United States

Swiss pharmaceutical giant Roche recently announced that the Food and Drug Administration (FDA) has accepted the biologics licensing application (BLA) of polatuzumab vedotin, antibody drug conjugate (ADC), and granted priority review. TheRead More…